Stoke Therapeutics gets Buy rating on promising late-stage trial for Dravet Syndrome drug zorevunersen.

Stoke Therapeutics has been initiated with a Buy rating due to positive progress in its phase 3 EMPEROR trial for zorevunersen, a treatment targeting SCN1A Dravet Syndrome. The trial aims to deliver data by mid-2027, with a rolling NDA submission expected in the first half of 2027. Three-year open-label data show sustained seizure reduction and functional improvement, indicating the drug's potential to modify the disease. The company’s strong cash position, partnership with Biogen, and low cash burn provide financial stability through mid-2028, reducing near-term financing risks.